Search Results 301-310 of 16965 for Hepatotoxicity

  1. A Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation - Mayo Clinic

    About this study. This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have ...

  2. Safety and Efficacy of Simtuzumab (GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH) - Mayo Clinic

    Safety and Efficacy of Simtuzumab (GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH) · Overview.

  3. Hematology - Clinical trials

    This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in ...

  4. Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  5. Gastroenterology and Hepatology - Doctors - Mayo Clinic

    Mayo Clinic's Division of Gastroenterology and Hepatology offers treatment and specialty care for people with a wide range of rare and common digestive ...

  6. A Study To Evaluate Efficacy And Safety Of Tulisokibart (MK-7240) In Participants With Moderately To Severely Active Ulcerative Colitis (MK-7240-001) - Mayo Clinic

    ... hepatotoxicity. Is on treatment with any of the following allowable drugs during the study and meets drug stabilization requirements, as applicable: Oral ...

  7. Genomic and Exposomic Hepatobiology: Konstantinos N. Lazaridis - Clinical trials, Clinical studies and Funding

    View clinical trials, clinical studies and funding information for Mayo Clinic's Genomic and Exposomic Hepatobiology Lab led by Konstantinos N. Lazaridis, ...

  8. A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment - Mayo Clinic

    About this study. The purpose of this study is to evaluate the safety and effectiveness, as determined by 90-day incidence of mortality or transplant, ...

  9. Request an appointment - Mayo Clinic

    In most cases, Mayo Clinic doesn't require a physician referral. Some insurers require referrals, or may have additional requirements for certain medical care.

  10. Medical Research & Education - Mayo Clinic News Network

    Video: A healthy liver transitions to cirrhosis, illustrating a potential outcome of metabolic dysfunction-associated steatotic liver disease — formerly known ...